The Dominican Republic is a nearshore Caribbean hub for first-in-human medical device studies, with direct US flights, defined regulatory authority through DIGEMAPS, and CONABIOS-overseen ethics review that averages ~30 days at the institutional REC level. Protocols follow the Declaration of Helsinki and CIOMS guidelines, and bioaccess® ensures data is FDA-submissible under 21 CFR 812.28 — at ~30% lower cost than US/EU programs.
The Dominican Republic combines a defined regulatory framework, an active national bioethics infrastructure, and direct US flight connectivity — a combination that makes it one of the more compelling nearshore Caribbean options for first-in-human medical device studies. It is a natural fit for US sponsors seeking geographic proximity, favorable time-zone alignment, and lower program cost.
The Ministry of Public Health, through its Directorate General of Medicines, Food and Health Products (DIGEMAPS), serves as the national regulatory authority. Ethics oversight is coordinated by the National Bioethics Council in Health (CONABIOS), which supervises Research Ethics Committees (RECs). Institutional REC review averages ~30 days, and CONABIOS-level review averages ~45 days (up to 120 depending on complexity).
Protocols in the Dominican Republic follow the Declaration of Helsinki and CIOMS guidelines. bioaccess® manages the complete pathway — DIGEMAPS submissions, REC and CONABIOS coordination, site qualification, and monitoring — so sponsors get FDA-quality first-in-human data at roughly 30% lower cost than a comparable US or EU program.
The Ministry of Public Health of the Dominican Republic, through its Directorate General of Medicines, Food and Health Products (DIGEMAPS), is the national regulatory authority for health products, including medical devices. bioaccess® prepares complete regulatory dossiers and coordinates directly with DIGEMAPS through study start-up.
The National Bioethics Council in Health (CONABIOS) oversees Research Ethics Committees (RECs) in the Dominican Republic. Institutional REC review averages approximately 30 days, and CONABIOS-level review averages approximately 45 days (up to 120 depending on complexity). bioaccess® coordinates ethics submissions at both levels and manages responses to committee questions.
Clinical research in the Dominican Republic follows the Declaration of Helsinki and CIOMS International Ethical Guidelines for Health-related Research Involving Humans. This alignment with globally recognized standards provides sponsors a defensible ethical framework for first-in-human device studies and supports downstream FDA submission.
Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from the Dominican Republic for IDE submissions and marketing applications, provided studies are conducted under ISO 14155 with proper DIGEMAPS authorization and CONABIOS-overseen ethics approval. bioaccess® designs every protocol for FDA submission from day one — with source data verification, monitoring plans, and documentation practices built around 21 CFR expectations.
| Metric | Dominican Republic 🇩🇴 | United States 🇺🇸 | Europe (EU) 🇪🇺 |
|---|---|---|---|
| Ethics + national review | REC ~30 days + CONABIOS ~45 days | 6–12 months (IDE + IRB) | 3–6 months (per-country CA + EC) |
| Regulatory authority | DIGEMAPS (Ministry of Public Health) | FDA | EMA / national CAs |
| Ethics oversight | CONABIOS (National Bioethics Council) | Local IRBs | Per-country ECs |
| Standards followed | Declaration of Helsinki + CIOMS | 21 CFR / ISO 14155 | ISO 14155 |
| FDA data acceptance | Eligible for submission/review — 21 CFR 812.28 (ISO 14155) | Native | Yes, with justification |
| Cost vs. US program | ~30% lower | Baseline | ~15–25% lower |
Regulatory details reflect published national frameworks; timelines and costs vary by device complexity, therapeutic area, and monitoring requirements. bioaccess® confirms the current pathway for each program.
The Ministry of Public Health, through its Directorate General of Medicines, Food and Health Products (DIGEMAPS), is the national regulatory authority for health products, including medical devices.
The National Bioethics Council in Health (CONABIOS) oversees Research Ethics Committees (RECs). Institutional REC review averages ~30 days, and CONABIOS-level review averages ~45 days (up to 120 depending on complexity).
Protocols follow the Declaration of Helsinki and CIOMS International Ethical Guidelines for Health-related Research Involving Humans, alongside ISO 14155 for FDA-submissible programs.
Yes. Under 21 CFR 812.28, foreign clinical data is eligible for FDA submission and review from the Dominican Republic when studies are conducted under ISO 14155 with proper DIGEMAPS authorization and CONABIOS-overseen ethics approval. bioaccess® designs protocols for FDA submission from the start.
Programs in the Dominican Republic typically run ~30% lower than a comparable US or EU program. Actual cost depends on device complexity, indication, monitoring intensity, and sample size — bioaccess® scopes each program individually.
The Dominican Republic combines a defined DIGEMAPS regulatory pathway, an active CONABIOS-overseen REC network with ~30-day institutional review, direct US flight connectivity, and ~30% lower program cost than US/EU baselines. It's a strong nearshore option for US sponsors.
All countries we serve · Contact bioaccess® · First-in-Human CRO